There are currently 189 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: The University of Arizona Cancer Center, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Recruiting
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
NCT05344833
Recruiting
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Myeloma
Register for Updates
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT02291848
Recruiting
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor asso... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Harris Health Ben Taub Hospital, Houston, Texas +2 locations
Conditions: Multiple Myeloma
Register for Updates
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
NCT06107738
Recruiting
The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are: * Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with resi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Multiple Myeloma
Register for Updates
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
NCT00898235
Recruiting
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Boston University Cancer Research Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
NCT06623630
Recruiting
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal function, leading to an urgent, unmet clinical need to develop safe and effective lymphodepleting regimens prior to CAR T administration for this population. In addition, renal insufficiency is linked... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
NCT06483100
Recruiting
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
Register for Updates
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135
Recruiting
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Arizona Oncology Associates, Tucson, Arizona +15 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Multiple Myeloma
Register for Updates
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT05093335
Recruiting
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
12/18/2024
Locations: Advent Health, Greenwood Village, Colorado +46 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates